More antibody with less antigen

Can immunogenicity of attenuated live virus vaccines be improved?

Alexander Bukreyev, Mario H. Skiadopoulos, Josephine McAuliffe, Brian R. Murphy, Peter L. Collins, Alexander C. Schmidt

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

New or improved vaccines against viruses such as influenza, parainfluenza types 1-3, measles, dengue, and respiratory syncytial virus would prevent an enormous burden of morbidity and mortality. Vaccines or vaccine candidates exist against these viral diseases, but all could potentially be improved if the immunogenicity of the vaccine could be enhanced. We found that the immunogenicity in primates of a live-attenuated vaccine candidate for parainfluenza virus type 3, an enveloped RNA virus that is an important etiologic agent of pediatric respiratory tract disease, could be enhanced by expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) from an extra gene inserted into the genome of a cDNA-derived virus. Expression of GM-CSF by the live attenuated recombinant virus did not perse affect the level of pulmonary viral replication in rhesus monkeys after topical administration, which was 40-fold lower than that of WT parainfluenza virus type 3. Despite that, the expressed extra gene augmented the virus-specific serum antibody response to a level that was (i) 3- to 6-fold higher than that induced by the same virus with an unrelated RNA insert of equal length and (ii) equal to the response induced by nonattenuated WT virus. In addition, topical immunization with the attenuated virus expressing GM-CSF induced a greater number of virus-specific IFN-γ-secreting T lymphocytes in the peripheral blood of monkeys than did immunization with the control virus bearing an unrelated RNA insert. These findings show that the immunogenicity of a live-attenuated vaccine virus in primates can be enhanced without increasing the level of virus replication. Thus, it might be possible to develop liveattenuated vaccines that are as immunogenic as parental WT virus or, possibly, even more so.

Original languageEnglish (US)
Pages (from-to)16987-16991
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume99
Issue number26
DOIs
StatePublished - Dec 24 2002
Externally publishedYes

Fingerprint

Attenuated Vaccines
Viruses
Antigens
Antibodies
Vaccines
Granulocyte-Macrophage Colony-Stimulating Factor
Human parainfluenza virus 3
Primates
Immunization
RNA
Respiratory Tract Diseases
Paramyxoviridae Infections
Topical Administration
Respiratory Syncytial Viruses
Dengue
RNA Viruses
Measles
Virus Diseases
Virus Replication
Macaca mulatta

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

More antibody with less antigen : Can immunogenicity of attenuated live virus vaccines be improved? / Bukreyev, Alexander; Skiadopoulos, Mario H.; McAuliffe, Josephine; Murphy, Brian R.; Collins, Peter L.; Schmidt, Alexander C.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, No. 26, 24.12.2002, p. 16987-16991.

Research output: Contribution to journalArticle

Bukreyev, Alexander ; Skiadopoulos, Mario H. ; McAuliffe, Josephine ; Murphy, Brian R. ; Collins, Peter L. ; Schmidt, Alexander C. / More antibody with less antigen : Can immunogenicity of attenuated live virus vaccines be improved?. In: Proceedings of the National Academy of Sciences of the United States of America. 2002 ; Vol. 99, No. 26. pp. 16987-16991.
@article{27f65e6ae1ce4574924d6d0be6a4657e,
title = "More antibody with less antigen: Can immunogenicity of attenuated live virus vaccines be improved?",
abstract = "New or improved vaccines against viruses such as influenza, parainfluenza types 1-3, measles, dengue, and respiratory syncytial virus would prevent an enormous burden of morbidity and mortality. Vaccines or vaccine candidates exist against these viral diseases, but all could potentially be improved if the immunogenicity of the vaccine could be enhanced. We found that the immunogenicity in primates of a live-attenuated vaccine candidate for parainfluenza virus type 3, an enveloped RNA virus that is an important etiologic agent of pediatric respiratory tract disease, could be enhanced by expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) from an extra gene inserted into the genome of a cDNA-derived virus. Expression of GM-CSF by the live attenuated recombinant virus did not perse affect the level of pulmonary viral replication in rhesus monkeys after topical administration, which was 40-fold lower than that of WT parainfluenza virus type 3. Despite that, the expressed extra gene augmented the virus-specific serum antibody response to a level that was (i) 3- to 6-fold higher than that induced by the same virus with an unrelated RNA insert of equal length and (ii) equal to the response induced by nonattenuated WT virus. In addition, topical immunization with the attenuated virus expressing GM-CSF induced a greater number of virus-specific IFN-γ-secreting T lymphocytes in the peripheral blood of monkeys than did immunization with the control virus bearing an unrelated RNA insert. These findings show that the immunogenicity of a live-attenuated vaccine virus in primates can be enhanced without increasing the level of virus replication. Thus, it might be possible to develop liveattenuated vaccines that are as immunogenic as parental WT virus or, possibly, even more so.",
author = "Alexander Bukreyev and Skiadopoulos, {Mario H.} and Josephine McAuliffe and Murphy, {Brian R.} and Collins, {Peter L.} and Schmidt, {Alexander C.}",
year = "2002",
month = "12",
day = "24",
doi = "10.1073/pnas.252649299",
language = "English (US)",
volume = "99",
pages = "16987--16991",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "26",

}

TY - JOUR

T1 - More antibody with less antigen

T2 - Can immunogenicity of attenuated live virus vaccines be improved?

AU - Bukreyev, Alexander

AU - Skiadopoulos, Mario H.

AU - McAuliffe, Josephine

AU - Murphy, Brian R.

AU - Collins, Peter L.

AU - Schmidt, Alexander C.

PY - 2002/12/24

Y1 - 2002/12/24

N2 - New or improved vaccines against viruses such as influenza, parainfluenza types 1-3, measles, dengue, and respiratory syncytial virus would prevent an enormous burden of morbidity and mortality. Vaccines or vaccine candidates exist against these viral diseases, but all could potentially be improved if the immunogenicity of the vaccine could be enhanced. We found that the immunogenicity in primates of a live-attenuated vaccine candidate for parainfluenza virus type 3, an enveloped RNA virus that is an important etiologic agent of pediatric respiratory tract disease, could be enhanced by expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) from an extra gene inserted into the genome of a cDNA-derived virus. Expression of GM-CSF by the live attenuated recombinant virus did not perse affect the level of pulmonary viral replication in rhesus monkeys after topical administration, which was 40-fold lower than that of WT parainfluenza virus type 3. Despite that, the expressed extra gene augmented the virus-specific serum antibody response to a level that was (i) 3- to 6-fold higher than that induced by the same virus with an unrelated RNA insert of equal length and (ii) equal to the response induced by nonattenuated WT virus. In addition, topical immunization with the attenuated virus expressing GM-CSF induced a greater number of virus-specific IFN-γ-secreting T lymphocytes in the peripheral blood of monkeys than did immunization with the control virus bearing an unrelated RNA insert. These findings show that the immunogenicity of a live-attenuated vaccine virus in primates can be enhanced without increasing the level of virus replication. Thus, it might be possible to develop liveattenuated vaccines that are as immunogenic as parental WT virus or, possibly, even more so.

AB - New or improved vaccines against viruses such as influenza, parainfluenza types 1-3, measles, dengue, and respiratory syncytial virus would prevent an enormous burden of morbidity and mortality. Vaccines or vaccine candidates exist against these viral diseases, but all could potentially be improved if the immunogenicity of the vaccine could be enhanced. We found that the immunogenicity in primates of a live-attenuated vaccine candidate for parainfluenza virus type 3, an enveloped RNA virus that is an important etiologic agent of pediatric respiratory tract disease, could be enhanced by expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) from an extra gene inserted into the genome of a cDNA-derived virus. Expression of GM-CSF by the live attenuated recombinant virus did not perse affect the level of pulmonary viral replication in rhesus monkeys after topical administration, which was 40-fold lower than that of WT parainfluenza virus type 3. Despite that, the expressed extra gene augmented the virus-specific serum antibody response to a level that was (i) 3- to 6-fold higher than that induced by the same virus with an unrelated RNA insert of equal length and (ii) equal to the response induced by nonattenuated WT virus. In addition, topical immunization with the attenuated virus expressing GM-CSF induced a greater number of virus-specific IFN-γ-secreting T lymphocytes in the peripheral blood of monkeys than did immunization with the control virus bearing an unrelated RNA insert. These findings show that the immunogenicity of a live-attenuated vaccine virus in primates can be enhanced without increasing the level of virus replication. Thus, it might be possible to develop liveattenuated vaccines that are as immunogenic as parental WT virus or, possibly, even more so.

UR - http://www.scopus.com/inward/record.url?scp=0037168606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037168606&partnerID=8YFLogxK

U2 - 10.1073/pnas.252649299

DO - 10.1073/pnas.252649299

M3 - Article

VL - 99

SP - 16987

EP - 16991

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 26

ER -